# New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

> **NCT00269438** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 225 (—)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** 5 ASA, enemas, suppositories, corticosteroids

## Key facts

- **NCT ID:** NCT00269438
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-03
- **Final completion:** 2007-06
- **Target enrollment:** 225 (—)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269438, "New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00269438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*